If you have been looking into medical cannabis in the UK, you have likely encountered a sea of conflicting information. As someone who spent nine years navigating NHS referral pathways and private clinic intake systems, I have seen the confusion that arises when patients encounter the intersection of strict regulation and commercialised healthcare.
In this post, I want to strip away the marketing fluff. We are going to look at what a "specialist evaluation" actually entails. This is not a process of "getting approved"; it is a process of clinical risk assessment. If you are seeking treatment, it is vital to understand that your medical records are the only currency that matters in this system.
The Legal Landscape: NHS vs. Private
To understand the evaluation, you must first understand the infrastructure. Since the law changed in 2018, cannabis-based products for medicinal use (CBPMs) have been legal. However, legality does not equate to routine accessibility.
The NHS remains the primary gatekeeper of public healthcare, but in the context of medical cannabis, its role is exceptionally limited. Most NHS consultants are currently advised against prescribing due to a lack of long-term clinical trials that meet the stringent National Institute for Health and Care Excellence (NICE) guidelines.
Consequently, the majority of patients engage with private clinics. This is a legitimate pathway, provided the clinics are registered with the Care Quality Commission (CQC). While these clinics operate commercially, they are still bound by the same GMC (General Medical Council) guidelines as their NHS counterparts. They cannot bypass the clinical rigour required to prescribe a controlled drug.
A Comparison of Pathways
Feature NHS Pathway Private Pathway Accessibility Highly restricted (mostly specialist paediatric/neurology) Broader for adults (chronic pain, psychiatry) Prescriber Status Specialist only Specialist only Cost Covered by the NHS Patient-funded (consultations and prescriptions) Gatekeeping Strict NICE criteria Individual clinic clinical governanceThe Specialist-Only Rule: Why GPs Cannot Initiate
I frequently hear patients ask, "Can my GP just write me a prescription for this?" The answer is, firmly, no. In the UK, a GP cannot initiate a prescription for medical cannabis. This is not because they lack the desire to help, but because the regulation dictates that only a consultant listed on the Specialist Register can initiate these treatments.
This is a safety mechanism designed to ensure that controlled substances are prescribed only by those with the specific expertise to manage the condition being treated. When you book a specialist evaluation, you are not talking to a general practitioner; you are entering a clinical relationship with a doctor who carries the legal weight of that prescription.
What is a Specialist Evaluation?
Many websites use the term "evaluation" to sound clinical, but it can be ambiguous. Let us define it clearly: A specialist evaluation is a formal clinical consultation where a doctor determines, based on your medical history, whether the potential benefits of cannabis-based medicine outweigh the clinical risks.
It is not a "guarantee of approval." It is not a consultation where you persuade a doctor to grant you access. It is an objective review of your pathology and your treatment history.
1. Documentation and Medical History: The Starting Point
This is the administrative bedrock of the process. Before a specialist even speaks to you, they require your Summary Care Record (SCR). This is not an optional document; it is the evidence required to prove you have a diagnosed condition.
What this step is: An objective audit of your previous medical interventions.
What this step is not: A casual conversation about your symptoms. If you cannot provide a record of a formal diagnosis, the process stops here. The specialist must here see evidence that you have sought conventional care first.
2. Treatment History Assessment
This is arguably the most critical part of the process. The specialist must confirm that you have exhausted or been intolerant to first-line, licensed treatments for your condition. If you are seeking treatment for chronic pain, for example, the clinician needs to see that you have tried standard analgesics, physiotherapy, or other recommended interventions.
What this step is: A verification that standard protocols have failed.
What this step is not: An entry point for "first-line" treatment. Medical cannabis is, in the current UK framework, a third- or fourth-line treatment. If you haven't tried the standard, evidence-based medications for your condition, a specialist will almost certainly advise you to do so before considering cannabis.
3. The Risk Review
This is where the clinician examines your individual health profile for "red flags." This includes checking for a history of psychosis, heart conditions, or other contraindications that might be exacerbated by cannabinoids. This is the stage where "clinical safety" is prioritised over the patient’s desire for a prescription.
What this step is: A thorough safety screening against contraindications.
What this step is not: A marketing exercise. If the risks are too high, the clinician is ethically and legally bound to refuse a prescription. Do not be surprised if a specialist declines treatment; they are prioritising your long-term safety over a quick approval.
4. The Suitability Check
Once the history and how much is medical cannabis risk profile are reviewed, the specialist makes a decision. This often involves a Multidisciplinary Team (MDT) review in more complex cases. The goal is to determine if the specific cannabinoids (THC/CBD ratios) can realistically manage your symptoms without causing secondary harm.
What this step is: A synthesis of clinical evidence and professional judgment.
What this step is not: A negotiation. You cannot "choose" a product; you are being assessed for suitability for a medication that the doctor deems appropriate for your specific case.
Managing Expectations: The Reality of the Pathway
If you are exploring this route, approach it with the same mindset you would use for any other medical procedure. The terminology used in advertisements—words like "fast," "instant," or "easy"—are marketing terms that have no place in a clinical setting.
The process is slow. It involves data transfer from your GP surgery to the private clinic, which can take weeks. It involves honest, sometimes difficult conversations about your medical history. It requires you to be patient with administrative delays.
Furthermore, because the field is still relatively new, clinicians are exceptionally cautious. They are under immense pressure to follow rigorous governance to keep their licenses. If you are asked for more documentation, or if you are asked to try a different conventional medication first, understand that this is standard procedure, not a personal slight.
Conclusion
Medical cannabis in the UK is a legitimate medical option, but it is not a "magic bullet." It is a highly regulated treatment pathway that prioritises safety above all else. When you sit down for that specialist evaluation, remember that you are not there to buy a product; you are there to receive a clinical assessment from a doctor whose priority is—or should be—your health outcomes.
If you take anything away from this, let it be this: organise your medical records before you contact a clinic. Have a clear, chronological history of what treatments you have tried, what the results were, and why they were insufficient. The clearer you make the administrative side of your history, the more efficiently the specialist can perform their clinical duty. Anything less than complete transparency in your medical history risks the entire evaluation process.
